Full Press Release Details
GlaxoSmithKline licensed from Immutep, rights to develop LAG 3 depleting antibodies for autoimmune disease 64m total deal package (~A$118m) + royalties GSK2831781 is currently in first time in human clinical trials (see NCT02195349 at clinicaltrials.gov) In January 2015, Prima announced a single digit million dollar milestone for the commencement of GSK s Phase I study GSK s investigational product aims to kill the few activated LAG 3+ T cells that are auto reactive in autoimmune disease leading to long term disease control Phase I: ongoing 10 IMP701 is partnered with Novartis IMP701 is an anti LAG 3 antibody which blocks LAG 3 mediated immune down regulation 2012: US biotech CoStim licensed LAG 3 antagonists for cancer from Immutep Feb. 2014: Novartis bought CoStim for undisclosed sum Phase I expected to start soon 11 CVac update CAN 003 Clear target patient population: in 2nd remission (CR2) of ovarian cancer Overall Survival Data with positive trend in CR2: 16 months benefit :42Mo CVac vs 25.53Mo OSC Progression free survival data: 8 months benefit: 12.91Mo for CVac versus PFS=4.94Mo for OSC Favorable safety data 12 Cancer treatment Cancer recurrence Tumour free: 1st Remission Cancer treatment Tumour free: 2nd Remission OUTLOOK FY2016 13 Funding cost savings Cash position at 30 th June 2015: $6.76 m SPP with $10 m Ridgeback Capital Investments LP funding: $13.8 m investment* Consolidation of CVac clinical trial program Staff reduction in FY 2015 (over 30%) Delisting from Deutsche B rse Trading OTC in Germany at no cost for Prima 14 Funded until end of 2016* *subject to shareholder approval at EGM Outlook upcoming FY 2016 Start of AIPAC Phase IIb study with IMP321 Start of immuno oncology combination Phase I study Continued development of Phase I study with IMP731 (GSK) Start of phase I study with IMP701 (Novartis) Potential new intellectual property Ongoing research Ongoing business development 15 THANK YOU! 16
Because actual results could differ materially to assumptions made and Prima BioMed s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. 2 Prima BioMed Clinical development of immuno oncology products Diversified portfolio with LAG 3 programs: Front positioning in growing immuno oncology revolution of cancer treatment 3 Mission: Emerging leader in immuno oncology Prima s development since last AGM Acquisition of well positioned biotech company Immutep closed in Dec 2014 Strengthening of management team GSK milestone payment Completion of CAN 003 trial with promising OS data Consolidating clinical development of CVac and focus on promising LAG 3 technology Commercial partnership with DBI for iCAN New IP for IMP321 Ridgeback financing Japanese collaboration with NEC Yamaguchi University for IMP321 Increased US interest (ADR increased from 2.66 m at end of Dec 14 to 17.71 m ADR s end of June 15) 4 Improved profile for Prima Development of the stock since last AGM 5 Update on Pipeline 6 Partner Preclinical Phase I Phase IIa Phase IIb Indication Eddingpharm (for China) Metastatic Breast Cancer + Chemotherapy Eddingpharm (for China) Metastatic Renal Cancer Others Eddingpharm (for China) IO Combination Therapy GlaxoSmithKline (WW) Autoimmune disease CoStim (Novartis) (WW) Cancer and chronic infectious disease Neopharm Group (for Israel) Ovarian Cancer IMP731 IMP701 CVac IMP321 Planned Planned IMP321 IMP321 IMP321 clinical development Chemoimmunotherapy Phase IIb trial in metastatic breast cancer Approx. 200 patients IMP321 with paclitaxel vs. paclitaxel and placebo Plan to start Q4 2015 Phase I in immuno oncology combination Planning phase of exciting combination study 7 Scientific advice from EMA received IMP321: AIPAC Study Design Multicenter, randomized, double blind, Phase IIb study Up to 200 patients with metastatic breast cancer Treatment: first line paclitaxel + IMP321 / placebo Primary objective: efficacy (as Progression Free Survival) Initiation after open label, safety run in phase: safety evaluation of recommended Phase II dose Primary geographical focus: Europe 8 IMP321: Potential Immuno oncology combination Study Design 9 Multicenter, open label, dose escalation, Phase I study Planning up to 30 patients with unresectable or metastatic cancer indication with dose escalation Treatment: Checkpoint inhibitor + IMP321 Primary objective: safety, tolerability Primary geographical focus: Australia or US IMP731 for autoimmune diseases Dec. 2010.
Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.
Please refer to the Company's website and/or the Company s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.
These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information.
ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 CEO Presentation Extraordinary General Meeting 1 Marc Voigt, Chief Executive Officer July 31, 2015 Sydney, Australia Exhibit 99.1 Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD; Deutsche B rse:YP1B.DE).